Quoin Pharmaceuticals, Ltd. QNRX
3.73 USD -0.17 (-4.48%)
At closeNov 10, 2026, 4:00 PM EST
3.81 +0.08 +2.14%
After hours · Nov 10, 4:00 PM ET
3.71 Day range 3.96
3.25 52-week range 23.50
- YTD
- -74.15%
- 1 year
- -54.18%
News
globenewswire.com Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome Kristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest…
benzinga.com Quoin Pharmaceuticals Q3 EPS $(0.97) Beats $(1.52) Estimate Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.52) by 36.18 percent. This is a 85.54 percent increase over losses…
globenewswire.com Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results – Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
benzinga.com Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published– Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient–…
benzinga.com Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18 Canaccord Genuity analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $18.- benzinga.com Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome – Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin…
benzinga.com This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating.
benzinga.com BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14 BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $14.